Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy.

Front Genet · 2023 · PMC10076713 · PMID 37035751

Europe PMC DOI

hedged sentence

0.6500

closest p · 13.0× alpha

0.6500

boldest claim

The sentences

borderline non-significantp = 0.65not close (p > 0.1)

The combination of any three or more biomarkers categorized as high also showed a significant difference in PFS ( p = 0.034) and borderline non-significant separation in OS ( p = 0.65) ( Figure 4A , middle-left).

also in 57 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.